Carlsmed Inc (CARL)

NASD · Healthcare · Health Information Services · USA

Carlsmed Inc is a small cap company (market value between $300 million and $2 billion) in the Health Information Services industry.

Carlsmed Inc is a medical technology company offering AI-enabled personalized spine surgery solutions for lumbar and cervical fusion procedures. The aprevo Technology Platform uses algorithms and patient imaging to create customized surgical plans and tailored interbody implants for each patient's anatomy. The company sells its devices to hospitals and surgical centers through direct sales and independent agents.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Carlsmed Inc stock.

Our verdict on CARL

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.

ETFs with the most weight in CARL

11 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Health Information Services

All 40 Health Information Services stocks

Cheaper than CARL in Health Information Services

13 more in this industry show a wider margin of safety.

Is CARL undervalued or overvalued?

We do not publish a verdict on CARL yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of CARL?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.